Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Indivior Pharmaceuticals (INDV) Change in Accured Expenses (2024 - 2025)

Historic Change in Accured Expenses for Indivior Pharmaceuticals (INDV) over the last 2 years, with Q3 2025 value amounting to -$82.0 million.

  • Indivior Pharmaceuticals' Change in Accured Expenses fell 92000.0% to -$82.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$14.0 million, marking a year-over-year change of. This contributed to the annual value of $8.0 million for FY2024, which is 9272.73% down from last year.
  • Indivior Pharmaceuticals' Change in Accured Expenses amounted to -$82.0 million in Q3 2025, which was down 92000.0% from $50.0 million recorded in Q2 2025.
  • In the past 5 years, Indivior Pharmaceuticals' Change in Accured Expenses registered a high of $81.0 million during Q1 2025, and its lowest value of -$82.0 million during Q3 2025.